Exogenous OXM improves glycemic control and insulin secretion in both animals and humans with obesity or T2DM, although its concurrent glucagon receptor activity may attenuate its glucose-lowering effects relative to GLP-1 receptor agonists [57, 59]. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.